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http://dx.doi.org/10.1016/j.ccr.2013.01.002SUMMARYEarly-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To
compare the genomic alteration landscapes of EO-PCA with ‘‘classical’’ (elderly-onset) PCA, we performed
deep sequencing-based genomics analyses in 11 tumors diagnosed at young age, and pursued comparative
assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural
rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. WhereasSignificance
It is presently unknownwhether genetic or mechanistic differences distinguish ‘‘classical’’ elderly-onset PCA from EO-PCA.
Using integrative high-throughput sequencing approaches, combined with validations in a large-scale patient cohort, we
show that EO-PCA formation involves a characteristic pathomechanism associated with the specific emergence of
androgen-driven SRs. By comparison, elderly-onset PCAs accumulate nonandrogen-associated SRs, indicating that
a different tumor formation mechanism is operating in these. This work reveals a striking age-dependent SR associated
disease mechanism in a common human cancer, and presents a significant advancement in understanding age-dependen-
cies of PCA initiation and progression, with implications for clinical management. The genomics data from our consortium
further provide a valuable compendium of massively-parallel DNA sequencing data in EO-PCA.
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Androgen-Driven Early-Onset Prostate CancerEO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS
gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated
SRs. Data from a validation cohort of > 10,000 patients showed age-dependent androgen receptor levels
and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a charac-
teristic ‘‘androgen-type’’ pathomechanism in EO-PCA.INTRODUCTION
Prostate cancer (PCA) is the most common cancer in Western
countries and the second most lethal cancer in men (Siegel
et al., 2012). The incidence of PCA increases with age, with
a median age at diagnosis of 70 years (Gro¨nberg, 2003).
Due to relatively slow disease progression when compared
to life expectancy, patients with PCA do not always require
definite therapy, with active surveillance representing an estab-
lished treatment option (Heidenreich et al., 2011). A relevant
subset of PCA, however, is diagnosed early in life, referred
to as early-onset PCA (EO-PCA), with 2% of all tumors
detected in men 50 years of age or younger (Figure 1). EO-
PCAs are of substantial clinical relevance, requiring obligatory
definite treatment (Heidenreich et al., 2011). This is due to
the high life expectancy of these young patients, with a higher
risk of dying of disease (Albertsen et al., 2005; Parker et al.,
2006), although there are also studies showing a more
pronounced risk of rapid death in EO-PCA (Lin et al., 2009b;
Ryan et al., 2007) compared to the ‘‘classical’’ cases of PCA
diagnosed in 60- to 80-year-old men (herein referred to as
‘‘elderly-onset PCA’’).
Initial genomics surveys focused on classical, elderly-onset
PCA have revealed a substantial diversity in somatic single
nucleotide variants (SNVs) (Berger et al., 2011; Kumar et al.,
2011), and identified recurrent SRs, including oncogene-acti-
vating gene fusion events (Berger et al., 2011; Bastus et al.,
2010; Lin et al., 2009a; Mani et al., 2009; Taylor et al., 2010; Tom-
lins et al., 2005) in elderly-onset PCAs. Despite the recent prog-
ress in identifying molecular drivers of PCA with massively-
parallel sequencing of cancer genomes (Berger et al., 2011)
and exomes (Kumar et al., 2011; Barbieri et al., 2012; Grasso
et al., 2012), so far no study has generated whole-genome
sequencing data of EO-PCAs. Hence, it has therefore remained
unclear whether EO-PCA is characterized by a distinctive
spectrum of driver mutations or a specific pathomechanism. A
better understanding of genomic alterations associated with
EO-PCA will facilitate the understanding of molecular defects
leading to early disease onset and foster the development
of new diagnostic, prognostic, therapeutic, and prevention
strategies.
On behalf of the International Cancer Genome Consortium
(ICGC) project on Early-Onset Prostate Cancer (http://www.
icgc.org), we carried out integrated genomic analyses, including
whole-genome, transcriptome, and DNA methylome sequenc-
ing (Campbell et al., 2008) in 11 patients with EO-PCA. We
used these genomics data, together with a large-scale tissue
microarray (Schlomm et al., 2008) (TMA)-based validation
platform, to pinpoint molecular features linked with early disease
occurrence.160 Cancer Cell 23, 159–170, February 11, 2013 ª2013 Elsevier Inc.RESULTS
Integrative High-Throughput Sequencing and Variant
Calling
Tumor and paired control tissue samples (lymphocytes) were ob-
tained from all 11 patients with EO-PCA who provided informed
consent. The patient mean age at surgery was 47 years, tumor
Gleason grades ranged from 3+4 to 5+4, and tumor stages
from pT2c to pT3b (Table 1). Our multitiered genomics approach
(see Experimental Procedures) involved 30- to 40-fold whole-
genome sequencing (Table 2; Figure S1A available online) of
tumor and control samples, with two sequencing libraries per
sample displaying complementary paired read insert sizes (ie,
200 bp paired-end, and 4.5 kb mate-pair inserts) (Ley et al.,
2008). We furthermore carried out transcriptome sequencing
(RNA-seq) (Sultan et al., 2008) of each tumor in comparison to
a normal prostate tissue control, using two complementary
library generation approaches geared toward assessing mRNAs
and MicroRNAs (miRNAs). In addition, we identified altered DNA
methylation patterns by performing an enrichment of methylated
DNA fragments with an Fc-coupled MBD2 protein (Gebhard
et al., 2006) followed by massively parallel sequencing (Figures
S1B and S1C; see Experimental Procedures).
Following the mapping of DNA reads onto the human refer-
ence assembly we applied complementary computational
approaches for the detection of somatic genome alterations
(see Experimental Procedures). We identified SNVs, as well as
short deletions and insertions (short InDels) by directly evalu-
ating read alignments onto the reference genome assembly (Li
and Durbin, 2009; DePristo et al., 2011). Furthermore, we de-
tected large-scale somatic structural rearrangements (SRs) by
evaluating the relative depth-of-coverage of DNA reads along
chromosomes, by scanning DNA reads for split or clipped read
alignments, and by identifying read-pairs that abnormally map-
ped onto the reference (Xi et al., 2011).
Altogether, we identified 931–5,696 somatic SNVs per patient
(Tables 2 and S1; Figure S1A), with the C > T nucleotide transition
being the most common substitution (42.6% ± 5.6%), similar to
what has been observed in elderly-onset PCAs (Berger et al.,
2011; Kumar et al., 2011). On average, 16 nonsynonymous
somatic SNVs fell into protein-coding genes (range 3–55),
affecting altogether 175 genes. We further detected six nonsy-
nonymous rare germline SNVs with a second somatic mutational
event, leading to compound heterozygosity (Table S1; Supple-
mental Experimental Procedures). A low number (four) of high-
confidence somatic InDels of %50 bp in size was identified
(Table S2). By comparison, we detected a considerably larger
number—20–90 per EO-PCA genome (average, 45)—of somatic
SRs (Tables 2 and S2; Figures 2A and S2A). These somatic
variants included copy-number alterations (average, 23), and
Figure 1. The Age Distribution in Elderly-
Onset PCA and EO-PCA
Dark and light areas depict patients younger than
50 years (EO-PCA) and patients between 50 and
60 years old, respectively (reproduced from
epidemiologic data; Gro¨nberg, 2003).
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(average, 22), most of which were translocations. PCR followed
by capillary sequencing verified 85 of 95 (89%) SNVs, all four
short somatic InDels, and 50 of 53 (94%) of the SRs (Table S3).
Computational Inference and Characterization
of Candidate Driver Somatic Alterations
To assess the functional relevance of these somatic alterations,
we first analyzed gene-altering events in detail. Because a
relevant portion of the somatic alterations identified may consti-
tute passenger alterations (Stratton et al., 2009), we performed
integrative analyses to infer candidate driver alterations in our
EO-PCA samples. This involved using our somatic SNV and
SR data to identify genes recurrently altered across samples,
and applying a ‘‘two-hit hypothesis’’ approach for the identifica-
tion of candidate tumor suppressor genes (Knudson, 1971), by
probing for genes for which both alleles were affected by geneticTable 1. Summary of Clinical Data for the 11 Patients with
EO-PCA
Patient ID
Age at
Surgery
(years)
pT
Stage
pN
Stage
Gleason
Score
Preoperative
PSA (ng/ml)
Family
History of
PCAa
EOPC-01 45 pT3a pN0 3+4 30.0 no
EOPC-02 51 pT2c pN0 3+4 23.8 NA
EOPC-03 46 pT3a pN0 5+4 12.0 no
EOPC-04 51 pT3b pN1 4+3 72.0 no
EOPC-05 50 pT3a NX 3+4 5.0 no
EOPC-06 38 pT3b pN1 3+4 18.2 NA
EOPC-07 49 pT2c pN0 3+4 5.4 yes
EOPC-08 44 pT2c pN0 3+4 7.8 yes
EOPC-09 48 pT2c pN0 3+4 5.1 no
EOPC-010 46 pT2c NX 3+4 6.0 no
EOPC-011 48 pT2c pN0 3+4 4.8 yes
All patients were diagnosed <50 years. All patients are of German
ancestry. PSA, prostate-specific antigen; NA, not applicable.
aAt least one first-degree relative with PCA.
Cancer Cell 23, 159–170,mechanisms of inactivation (see Experi-
mental Procedures). Our search strategy
resulted in the identification of 23 genes
that were disrupted or mutated in at least
two additional PCA patient cohorts (Bar-
bieri et al., 2012; Berger et al., 2011;
Grasso et al., 2012). We further inferred
76 genes harboring two genomic hits,
a list comprising several previously
described tumor suppressors includingCDH1, TP53, PTEN, and NCOR2, many of which also showed
promoter hypermethylation in samples not carrying the respec-
tive genetic lesion (Table S4).
NCOR2, a transcriptional corepressor interacting with the
androgen receptor (AR), was previously reported as mutated in
PCA (Taylor et al., 2010). In addition to biallelic genetic alter-
ations affecting NCOR2 in one tumor (EOPC-06), we observed
homozygous loss of an NCOR2 regulator in another tumor
(EOPC-04) in conjunction with NCOR2 downregulation. We
further identified high levels of DNA methylation of the NCOR2
promoter in association with NCOR2 downregulation in a third
tumor (EOPC-01). The clinical relevance of NCOR2 deletions
was evaluated with our large-scale TMA resource (Schlomm
et al., 2008) revealing NCOR2 deletions in 3.2% (163/5100)
PCAs, and showing significant association with biochemical
disease recurrence (p = 0.039, Likelihood ratio test; Figure S2B).
A pronounced diversity of inactivating genetic mechanisms
was also observed for PTEN, in agreement with a recent study
of elderly-onset PCAs (Reid et al., 2012). Namely, PTENwas dis-
rupted by a translocation in sample EOPC-05, also harboring
a large (55 Mb) deletion removing the other PTEN allele, with
our transcriptome data showing a pronounced PTEN downregu-
lation (Figure 2B). Analysis in a large patient cohort revealed
a high frequency of homozygous PTEN losses involving such
combinations of disruptive events, which are linked with
biochemical disease recurrence (Figures S2C–S2J). The addi-
tional finding of multiple upregulated PTEN-targeting miRNAs
(Figures S2K–S2O; Tables S5, S6, and S7) indicates the involve-
ment of different mechanisms of PTEN inactivation in PCA.
An Abundance of Gene-Fusing Rearrangements,
Including such Leading to ETS Fusion Genes, in EO-PCA
The striking abundance of balanced SRs in our EO-PCA
samples—with approximately half of all SRs being balanced
(a higher number than that recently reported [<30%] in elderly-
onset PCAs; Berger et al., 2011)—prompted us to investigate
in further detail the formation of gene-fusing rearrangements,
because fusion gene formation is frequently associated with
balanced SR formation (Rubin et al., 2011; Tomlins et al.,
2005). Indeed, we could identify a relatively large numberFebruary 11, 2013 ª2013 Elsevier Inc. 161
Table 2. Sequence Data and Somatic Genome Alterations in 11 EO-PCAs
Patient ID EOPC-01 EOPC-02 EOPC-03 EOPC-04 EOPC-05 EOPC-06 EOPC-07 EOPC-08 EOPC-09 EOPC-010 EOPC-011
Bp (paired)
(tumor/blood)
179/165 110/135 245/99 112/230 105/102 141/135 104/100 139/102 110/134 151/148 104/102
Sequence
coverage
423/443 303/263 693/303 323/653 313/303 413/403 313/303 293/313 333/403 463/443 313/303
PE physical
coverage
303/333 213/243 753/283 303/763 293/283 383/363 293/273 383/293 273/333 403/393 273/273
MP physical
coverage
143/173 153/153 163/163 163/113 173/153 163/183 133/173 173/203 183/183 173/173 183/183
mRNA-Seq reads
(million reads/Gb)
18/14 9/7 10/7 10/8 13/11 14/11 13/10 12/10 16/13 14/10 13/10
miRNA-Seq
in M reads
(total/mapped
to miRNAs)
NA NA NA NA 144/ 19 66/ 16 71/ 26 82/ 12 74/9 74/ 11 92/ 24
Methylome
reads in M
(total/mapped)
67/21 89/23 75/20 85/24 62/16 119/22 143/30 115/24 169/32 128/27 88/21
Somatic SNVs 5,696 3,747 4,529 2,430 1,475 1,277 1,404 931 985 1,536 1,567
Mutations
per Mb
2.0 1.3 1.6 0.8 0.5 0.4 0.5 0.3 0.3 0.5 0.5
Nonsilent
coding SNVs
55 11 40 21 6 8 9 6 3 10 6
Nonsilent InDels 1 1 0 0 0 0 1 1 0 0 0
Somatic Dels
(genes/Mb)
1452/235 442/101 671/124 598/84 1,043/194 2,283/347 961/153 524/91 481/93 771/144 566/125
Somatic Dups
(genes/Mb)
138/18.8 1/0.0 4/1.0 45/6.7 0/0.0 21/2.2 1/0.6 7/1.5 15/ 2.3 1/0.0 42/ 9.7
Translocation
(coding/
noncoding breaks)
15/11 12/8 14/4 32/40 27/27 38/20 14/4 11/1 21/5 11/1 26/18
Inversions
(coding/noncoding
breaks)
3/1 2/8 1/1 11/7 2/4 10/4 2/10 2/0 21/7 3/3 10/6
Estimated tumor
purity (%)
50 40 37 55 45 47 60 61 44 50 51
Production centers—sample acquisition and nucleic acid isolation: Martini Clinic, Prostate Cancer Center, and Institute of Pathology, University Clinic
Hamburg-Eppendorf (UKE); paired-end (PE) whole-genome sequencing: Max Planck Institute for Molecular Genetics (MPIMG), German Cancer
Research Center (DKFZ), and European Molecular Biology Laboratory (EMBL); long-range paired-end, or mate-pair (MP), genomic sequencing:
EMBL; transcriptome sequencing: MPIMG; miRNA sequencing: DKFZ; methylome sequencing: DKFZ. NA, not available.
See also Figure S1and Table S1.
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EO-PCA samples, 109 of which resulted from balanced SRs
(mostly translocations). While many of these gene-fusing events
were out-of-frame and likely correspond to passenger events,
most in-frame fusion genes received additional support from
mRNA-seq reads mapping directly over the junction point of
the fusion, or by the striking overexpression of the 30 fusion
partner (Table S2), suggesting their possible biologic relevance.
Fusion genes supported by marked expression upregulation
included the prototypical ETS gene family-associated fusion
genes TMPRSS2:ERG and SLC45A3:ERG (Tomlins et al.,
2005, 2007). Furthermore, we observed evidence for 17 rare
(nonrecurrent) previously undescribed in-frame gene fusion
events (Table S2). These included SNURF:ETV1, which evidently
was formed in conjunction with a complex rearrangement event162 Cancer Cell 23, 159–170, February 11, 2013 ª2013 Elsevier Inc.(closed chain; Berger et al., 2011) involving an androgen-
regulated 50-end fusion gene partner (SNURF) that, based on
our mRNA-Seq data, led to marked overexpression of an ETV1
open reading frame with previously demonstrated oncogenic
activity (Tomlins et al., 2007) (Figures 2C and S2P–S2T). We
also identified 17 fusion gene transcripts that were exclusively
discovered in our mRNA-seq data, ie, events missed by our
DNA sequencing-based SR detection pipeline (see Supple-
mental Experimental Procedures).
Early-Onset Prostate Cancers Harbor a Distinctive
Landscape of Genetic Rearrangements
The conspicuous frequency of gene-fusing SRs in EO-PCA
prompted us to perform a more detailed comparison between
the genomic landscapes of young and elderly patients, by
Figure 2. Genomes of EO-PCA Revealed by
High-Throughput Sequencing
(A) Circos plots, depicting genomic and epi-
genomic somatic aberrations in three EO-PCA
patients (all 11 EO-PCA genomes are displayed in
Figure S2A). Displayed features from outer to inner
ring include chromosomes (black) with cytobands
(gray) in the first ring; lines in second ring refer to
genes, with colors highlighting CancerCensus
genes (Futreal et al., 2004) (blue), biallelic in-
activated genes (red), nonsynonymous SNVs
(purple), inferred gene-disrupting deletions
(orange), gene-disrupting inversions (light blue)
and gene-disrupting translocations (light green);
squares in third ring refer to hypermethylated
(dark green) and hypomethylated DMRs (light red);
the fourth ring displays somatic inferred copy-
number gains and losses as read-depth plots; the
innermost shows translocations (green), deletions
(orange), inversions (light blue), and duplications
(gray).
(B) Biallelic inactivation of PTEN by combined
loss-of-heterozygosity and a disruptive t(1;10)
translocation in EOPC-05. RNA expression values
are depicted up- and downstream of the break-
point, along with the inferred copy-number profile
of the tumor sample relative to germline control
(log2 DNA read-depth ratio), with losses indicated
in yellow and gains in green. Gene expression
values are displayed in terms of the RNA-seq
read-depth (red) and averaged RPKM (light blue)
values upstream and downstream of the insertion
event.
(C) Rearrangements leading to the identified
SNURF:ETV1 fusion in EOPC-03, comprising up to
intron 2 of SNURF at the 50-end, and continuing
from intron 4 of ETV1 at the 30-end.
See also Figure S2 and Tables S2, S3, S4, S5, S6,
and S7).
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recently published whole-genomes of seven elderly-onset
(‘‘classical’’) PCAs, with a mean age at diagnosis of 65 years
(Berger et al., 2011). Relative to the total number of somatic
rearrangements, EO-PCAs indeed displayed a significantlyCancer Cell 23, 159–170,higher portion of SRs leading to gene-
fusing events (25% in EO-PCA versus
10% in the elderly; ie, 2.5-fold enrichment
with p = 0.001; Welch’s two-sample
t test; Figure 3A). This was despite an
overall lower number of SRs in EO-PCA
compared to elderly-onset PCA genomes
(average 45 versus 108 rearrangements,
respectively; p = 0.038, Welch’s two-
sample t test; Figure 3B), a trend that
we also confirmed upon reanalysis of
the raw DNA sequence read data from
Berger et al. using our computational SV
detection pipeline (see Supplemental
Experimental Procedures).
By comparison, when assessing
somatic SNVs, we observed no signifi-cant difference between EO-PCAs and elderly-onset PCAs in
terms of genome-wide (or protein-coding sequence-wide) SNV
counts (Table S1). Hence, despite marked differences evident
at the level of SRs, no such differences appeared to exist at
the level of SNVs.February 11, 2013 ª2013 Elsevier Inc. 163
Figure 3. Whole-Genome Sequencing-Based Analyses Reveal that EO-PCAs Harbor a Markedly Different SR Landscape than Elderly-Onset
PCAs
(A) Proportion of SRs leading to gene fusions. These analyses considered all breakpoints affecting Refseq gene models.
(B) SRs identified per sample.
(C) Fraction of gene rearrangements affecting androgen-regulated genes.
(D) Fraction of SRs intersecting high-confident androgen-receptor binding sites (ARBS) using a 50-kb search window.
(E) Portion of tumors harboring ETS fusion genes.
Welch’s two-sample t test was used to compute p values in (A)–(D). Boxplots display the 25th to 75th percentiles (boxes), medians (lines), and 1.5 times the
interquartile range (whiskers).
See also Table S2.
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Driven Somatic Genome Alteration Landscape
Because gene-fusing events in PCA can be mediated directly
upon activation of the AR (Mani et al., 2009), facilitating gene
fusion events that involve androgen-regulated genes bound by
the AR (Rubin et al., 2011), we hypothesized that the observed
differences in the somatic SR spectrum of EO-PCA versus
elderly-onset PCA may have resulted from the differential
usage of an AR-dependent SR formation mechanism driving164 Cancer Cell 23, 159–170, February 11, 2013 ª2013 Elsevier Inc.specific DNA rearrangements. To test this hypothesis, we first
generated a catalog of genes under androgen-regulation, by
measuring differential expression before and after dihydrotes-
tosterone-stimulation of LNCaP cells using gene expression
microarrays (see Supplemental Experimental Procedures and
Table S2). Strikingly, we observed a significantly higher fraction
of gene rearrangements affecting androgen-driven genes—in
which a break occurred in a gene differentially expressed upon
dihydrotestosterone-stimulation—in EO-PCA compared to
Figure 4. TMAVerifiesDistinct Age Spectra of Androgen-Dependent
and -Independent Progression Types
(A) Large-scale TMA analyses depict age relationships of the androgen-driven
ETS-fusion protein TMPRSS2:ERG in EO-PCA, and of nonandrogen-associ-
ated rearrangements in elderly-onset PCA. Frequency of assessed protein
(rings) and binomial logistic regressions (lines) depict ERG overexpression
(blue; n = 9,567), TMPRSS2:ERG fusion gene presence (orange; n = 6,071),
chromosome 6q deletion (purple; n = 3,493), and PTEN deletion/disruption
(green; n = 5,374) as a function of patient age (age at diagnosis ranging
between 36 and 80 years). ERG overexpression was detected by immuno-
histochemistry, and genomic rearrangements by FISH. P values are based on
binomial logistic regression.
(B) Proposed tumor progression models for androgen-type PCAs.
See also Figure S3.
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Celderly-onset PCA (Figure 3C; p < 0.01; Welch’s two-sample
t test). In further support of these findings, we observed a statis-
tical enrichment of AR signaling and WNT signaling (which inter-
acts with AR signaling in PCA; Yang et al., 2006) pathways
among genes involved in gene fusion events in EO-PCAs, but
not in elderly-onset PCAs (see Experimental Procedures and
Table S2). These findings indicate a prevalence of EO-PCA to
acquire specific, androgen-driven, somatic genome alterations.
AR binding to nuclear DNA can facilitate genomic rearrange-
ments through recruitment of topoisomerase 2B (TOP2B),
leading to DNA double strand break formation within or nearby
transcriptional hubs, joining different sections of the genome
that upon breakagemay reconnect to lead to intra- or inter-chro-
mosomal SRs (Haffner et al., 2010; Lin et al., 2009a). Hence, we
followed the assumption that if androgen drives the formation of
SRs characteristically arising in EO-PCA, we would observe
a relative enrichment of genomic AR binding sites near the
breakpoints of SRs in EO-PCA relative to elderly-onset PCA.
High-confidence binding sites of the AR were recently mapped
in LNCaP cells by chromatin immunoprecipitation followed by
massively parallel sequencing (ChIP-Seq), upon androgen stim-
ulation (Urbanucci et al., 2012). Indeed, when relating these
ChIP-Seq data to our SR data, we observed a marked enrich-
ment of SRs intersecting with AR binding sites (Urbanucci
et al., 2012) in EO-PCA compared to elderly-onset PCA (Fig-
ure 3D; p < 0.05, Welch’s two sample t test). These results are
consistent with the chromosomal looping by the AR bound to
its cognate binding sites specifically facilitating SRs in EO-PCA
in an androgen-driven manner.
ETS Fusion Genes Are a Hallmark of Early-Onset
Prostate Cancer
We next assessed the status of ETS family oncogene containing
fusion genes, with ETS fusions representing prototypic PCA
driver gene rearrangements mediated by androgen stimulation
and the AR (reviewed in Rubin et al., 2011). Even though the
number of sequenced PCA genomes is presently small, compar-
ison of the ETS rearrangement status in 11 EO-PCAs versus the
seven elderly-onset PCAs published by Berger and coworkers
already revealed statistically significant differences, with 10 of
11 (90%) EO-PCAs, but only three of seven (40%) elderly-
onset PCAs harboring such androgen-driven ETS rearrange-
ments (Figure 3E; p = 0.047; two-sided Fisher’s exact test).
Notably, the abundance of ETS fusions in EO-PCA was further
supported by our reanalysis of data published by Barbieri
et al., a study in which four of five patients%50 years harbored
TMPRSS2:ERG-fusions, compared to 54 of 107 patients > 50
years (Barbieri et al., 2012).
To verify the specific abundance of androgen-driven SRs in
EO-PCA in a larger patient cohort, we made use of our TMA
resource, covering thousands of patients (Figure 4A). We used
a surrogate for assessing androgen-driven ETS gene fusion
events, by applying a break-apart FISH probe for evaluating
the presence of the prototypical androgen-driven TMPRSS2:
ERG fusion gene (Lin et al., 2009a; see Experimental Procedures)
in patients with a disease age-of-onset of 36–80 years. Indeed,
the TMA analyses verified the continuous and significant relative
increase of the ETS gene fusion TMPRSS2:ERG (p < 2 3 1015,
logistic regression) in patients with early disease onset, henceancer Cell 23, 159–170, February 11, 2013 ª2013 Elsevier Inc. 165
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sequencing of an abundance of androgen-driven alterations in
EO-PCA (Figures 4A and S3). Because ERG gene fusions may
involve androgen-regulated genes other than TMPRSS2, we
additionally measured ERG protein expression by immunohisto-
chemistry (IHC), an analysis that further substantiated the
marked overexpression of ERG (p < 4 3 1025, logistic regres-
sion) in young versus elderly patients (Figures 4A and S3).
Nonandrogen-Associated Structural Rearrangements
Frequently Accumulate in Elderly-Onset Prostate
Cancer
Because SRs affecting androgen-regulated genes are markedly
enriched in EO-PCAs, whereas elderly-onset PCAs show an
overall higher load of SRs (Figure 3), we screened several addi-
tional recurrent SRs (Sun et al., 2007) for a relationship with
patient age at diagnosis, including those that do not involve
androgen-regulated genes. To this end, we performed extensive
FISH analyses, targeting the chromosome 6q15 region (Liu et al.,
2007b), the PTEN locus (Krohn et al., 2012), the CHD1 locus
(Huang et al., 2012), and NCOR2. Our data showed a significant
increase of 6q15, PTEN, and CHD1 genomic breaks, all of which
are not considered to be androgen-regulated, in elderly patients
(Figures 4A and S3)—findings that were independent of tumor
stage or Gleason grade (see also Table S2, which presents
data from detailed assessments of PTEN and ERG). These
results show that nonandrogen-associated SRs accumulate in
elderly-onset PCA. As a consequence, elderly-onset PCAs
acquire high loads of SRs, most of which correspond to copy-
number unbalanced alterations.
By comparison, deletions ofNCOR2were significantly associ-
ated with young age (Figure S3). Because NCOR2 is an AR
corepressor (Hodgson et al., 2005; Godoy et al., 2012), deletions
of this gene are predicted to lead to increased AR levels and in
turn may contribute to androgen-driven rearrangements in
young patients.
Increased Levels of Androgen or Its Receptor May
Explain the Early Disease Onset in Androgen-Driven
PCAs
The high abundance of androgen-driven genetic alterations in
EO-PCA suggests a relevance of those alterations for the
timing and initiation of tumorigenesis in the cells of the prostate.
Specifically, the preponderance of androgen-driven SRs in
young patientsmay intuitively be explained by a particularly early
development of tumors occurring in young patients (tumor-
onset model; Figure 4B). Alternatively, particularly rapid growth
kinetics of androgen-driven tumors may also explain the ob-
served age relationship (tumor-kinetic model; Figure 4B).
Because the initiation of tumorigenesis in the prostate cannot
be confidently ascertained in humans—with PCAs initiating
years or decades before being diagnosed (Knudsen and Vasiou-
khin, 2010)—we sought to evaluate the possible role of tumor
kinetics in the abundance of androgen-driven genetic alterations
in EO-PCA. We therefore employed IHC to measure cancer cell
proliferation using the Ki67 labeling index (LI) as a marker
(Bubendorf et al., 1996). Importantly, while growth kinetics
differed markedly between tumor grades (Figure 5A), there
were no observable differences between the growth kinetics of166 Cancer Cell 23, 159–170, February 11, 2013 ª2013 Elsevier Inc.androgen-driven (using ERG positivity as a proxy) versus nonan-
drogen-associated (ERG-negative) tumors (Figure 5A). Further-
more, there was no correlation between cancer cell proliferation
and age at diagnosis (R20; p = 0.44, Spearman’s rank correla-
tion). Hence, we can practically exclude a role of growth kinetics
in facilitating androgen-driven cancer occurrence in young
patients. Furthermore, the overall similar aggressive potential
of androgen-driven (ERG-positive) tumors versus nonandro-
gen-associated (ERG-negative) tumors is consistent with tumor
growth kinetics playing no marked role in generating the herein
observed age-associated SR spectra (Figure S4A). Hence, we
conclude that differences in the age-of-initiation of tumors
harboring androgen-driven SRs versus those not showing an
abundance of such SRs must have resulted in the characteristic
somatic DNA alteration landscapes of EO-PCA versus elderly-
onset PCA (Figure 4B).
Androgen Receptor Levels Are Elevated in Early-Onset
Prostate Cancer
Our findings hence point toward a crucial role of androgen and
AR activation in shaping the genomic landscape of PCAs, and
driving tumor initiation, motivating further in vivo analyses. While
it is impossible to estimate testosterone levels retrospectively in
patients during cancer initiation and evolution, patterns of AR
activity can be studied in tumor samples by measuring AR
protein expression (as a surrogate) in tumor samples at diag-
nosis (Lee and Chang, 2003). We pursued AR expression
analysis using IHC, relating AR levels to patient age and ERG
status. Importantly, our data revealed both a significantly
increased AR level in young patients (Figures 5B and 5C) and
a significant positive correlation of AR levels with ERG rearrange-
ments (p < 4 3 108 and p < 2 3 1012, respectively; Figure 5C;
see also Figures 5B–5D, S4B, and S4C). Hence, high AR expres-
sion levels are associated with ERG rearrangements and young
age, indicating an age-dependent activity of AR in PCA. ERG,
when highly expressed, was shown to lead to an inhibition of
AR expression in PCA cell lines (Yu et al., 2010), which makes
an inverse scenario in which ERG rearrangements result in
high AR levels exceedingly unlikely. Hence, our data indicate
a key role of androgen, and the AR, in mediating age-dependent
genomic alterations characteristically observed in EO-PCA.
DISCUSSION
PCA is typically characterized by a prolonged clinical coursewith
an estimated disease onset one to two decades prior to clinical
diagnosis (Lilja et al., 2007). Our genomics data based on
massively parallel DNA sequencing, comprising the largest
number of PCA whole-genomes sequenced to date, show that
most EO-PCAs involve an androgen-driven pathomechanism
characterized by a marked absolute and relative abundance of
DNA structural alterations involving androgen-regulated genes
(‘‘androgen-type prostate cancer’’). Our data are consistent
with a role of tumor onset, rather than tumor growth kinetics, in
driving the early occurrence of androgen-type PCA.
It is tempting to speculate that this early development of
androgen-type PCA may be driven by a particularly strong AR
activation, eg, by high testosterone levels, associated with
young patient age. It has previously been established that
Figure 5. EO-PCA Is Associated with High AR levels
(A) Proliferation rates, measured by KI67 IHC staining, for high- and low-grade PCAs, and specifically for ERG positive (proxy for androgen-driven; n = 2,888) and
ERG-negative tumors (proxy for nonandrogen-associated; n = 3,095). Low, Gleason grade < 4+3; High, Gleason gradeR 4+3; KI67 Labeling Index, LI.
(B) Age-relationship of AR overexpression, detected as strong, moderate, or weak expression based on judgment of IHC staining intensity by an experienced
pathologist (see Supplemental Experimental Procedures).
(C) Age-related interaction between AR overexpression and ERG rearranged tumors. Logistic regression of tumors with AR overexpression (yellow line, n = 4,668;
p = 3.553 108), and tumors with both AR and ERG overexpression (AR3 ERG; frequency of tumors displaying both ERG and AR overexpression, red line, n =
4,172; p = 1.80 3 1012; logistic regression).
(D) AR overexpression in ERG-positive and ERG-negative tumors (n = 4,172; p values based on Fisher’s exact test). Boxplots in (A) display the 25th to 75th
percentiles (boxes), medians (lines), and 1.5 times the interquartile range (whiskers). Notches show the 95% confidence interval of the median. n.s., not
significant.
See also Figure S4.
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decrease with age (Liu et al., 2007a; Mohr et al., 2005; Fig-
ure S4B) in a manner that remarkably parallels our observed
age-associated decrease of ERG positivity in PCA. Furthermore,
in vitro-data have demonstrated that the formation of ERG
rearrangements can be induced by serum androgen levels in
prostate epithelial cells (Lin et al., 2009a; Mani et al., 2009)Cthrough a mechanism involving inter- or intra-chromosomal
transcriptional hubs with co-recruitment of TOP2B, resulting in
SR-inducing DNA double-strand breaks (Haffner et al., 2010;
Lin et al., 2009a). Increased AR levels in young patients, which
we established by in vivo measurements at diagnosis, provide
further support to a crucial role of androgen in EO-PCA. In
addition, the strong link seen between AR expression andancer Cell 23, 159–170, February 11, 2013 ª2013 Elsevier Inc. 167
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older than 70 years suggests that high AR expression, and hence
activity, may result in androgen-type PCA, with androgen-driven
SRs irrespective of patient age.
Importantly, our finding of a specific pathomechanism
driving EO-PCA may be of relevance for a tailored clinical
management. Androgen-mediated rearrangements cause a
complex androgen-associated modulation of transcriptional
patterns and cellular pathways (Brase et al., 2011), with potential
consequences for disease progression and response to
androgen-ablative treatment in EO-PCA. Furthermore, cancer
screening by detection of androgen-mediated rearrangements,
eg, from biopsies, circulating tumor cells, or free circulating
DNA, may be particularly effective in young men.
With over 200 PCA samples having already been subjected to
exome sequencing (Barbieri et al., 2012; Grasso et al., 2012;
Kumar et al., 2011), the identification of previously uncharacter-
ized recurrent somatic SNVs affecting protein-coding regions
is becoming exceedingly challenging. At the same time,
approaches for clinical validation are becoming increasingly
relevant. In this regard, our study shows the utility of evaluating
genetic findings on large-scale TMAs containing thousands of
samples. Moreover, our study emphasizes the power of whole-
genomic sequencing, revealing information on mechanisms of
SR formation by ascertaining genetic variants beyond those
detectable by exome sequencing. Our genome-based findings
on SR formation in conjunction with large-scale FISH and
IHC-based assessment of ERG and AR enabled us to find
a remarkable missing link in the relationship of the AR, somatic
genome alterations, and PCA subtypes. In summary, our find-
ings demonstrate striking age-dependent differences in the
mechanistic landscapes of structural genomic alterations in
a common cancer.
EXPERIMENTAL PROCEDURES
Patients
Informed consent and an ethical vote (institutional reviewing board) were ob-
tained according to the current ICGC guidelines (see http://www.icgc.org).
The patients did not receive any neo-adjuvant radiotherapy, androgen depri-
vation therapy, or chemotherapy prior to the surgical removal of tumor tissue.
Tumor samples and one normal prostate control were frozen at 20C and
subsequently stored at 80C.
DNA Library Preparation and Sequencing
DNA library preparation and whole-genome sequencing was performed on
Illumina sequencers as described recently (Rausch et al., 2012a) with the
raw length of the reads displaying a median of 101 bp for short paired-end
insert-size libraries and 36 bp for large insert-size mate-pair libraries, and
a median insert-size of the sequenced libraries of 155–206 bp (short insert-
size paired-end), and 4,265–5,350 bp (large insert-size mate-pairs).
DNA Read Mapping and Sequence Variant Calling
Reads were aligned to the hg19 assembly of the human reference genome
using the proprietary ELAND2 tool from Illumina, as well as the BWA tool
(Li and Durbin, 2009). Post-processing of the aligned reads included merging
of lane-level data and removal of duplicate read-pairs using Picard tools
(http://picard.sourceforge.net). Only uniquely aligned reads were considered
for downstream mutation analysis. Aligned reads were converted to the
SAM/BAM format using SAMtools (Li et al., 2009), before initiating a set of
complementary variant calling algorithms. We applied three distinct com-
putational pipelines for SNV discovery, and subsequently kept SNV calls if168 Cancer Cell 23, 159–170, February 11, 2013 ª2013 Elsevier Inc.they were identified by at least two out of the three pipelines (Details and
parameters are in the Supplemental Experimental Procedures). InDels were
called using the Genome Analysis Toolkit (GATK) (DePristo et al., 2011) and
SAMtools (Li et al., 2009) mpileup. Consensus InDels were manually inspected
to identify potential misalignments. SRs 200 bp to megabases in size were
detected using the DELLY tool (Rausch et al., 2012b), as previously described
(Rausch et al., 2012a), employing discordantly mapping read-pairs, split-read
analysis (using an approach comparable to the soft-clipping functionality of
CREST; Wang et al., 2011), as well as sequencing depth-of-coverage (for
further details, see Supplemental Experimental Procedures). PCR verification
and Sanger sequencing of sequence variants was performed as previously
described (Rausch et al., 2012a). The False Discovery Rate (FDR) was ob-
tained for randomly picked SNVs with a minor allele frequency (MAF) greater
than 0.15 (to enable capillary sequencing-based data interpretation). We
further validated a number of SNVs below 0.15 MAF (marked in gray in Table
S3; see also Figure S1A).
mRNA Library Sequencing and Analysis
Strand-specific mRNA sequencing libraries were prepared from 10 mg of total
RNA as recently described (Parkhomchuk et al., 2009). However, instead of
shearing the cDNA, we fragmented the RNA PolyA+ fraction. The following
modifications were implemented: the purified polyA+ RNA fraction was
fragmented at 70C for 5 min using RNA fragmentation reagents (Ambion,
Cat. no. AM8740) and following the manufacturer instructions; the first strand
synthesis was performed with random hexamers (dN)6 primers. Sequencing
was carried out with 2 3 51 cycles on the Illumina HiSeq2000 instrument
(further details are in the Supplemental Experimental Procedures). Reads
were aligned to the hg19 genome assembly using BWA (0.5.9-r16) (Li and
Durbin, 2009). For calculation of fusion gene expression values, RNA-seq-
derived average exon RPKM values were extracted 50 and 30 to the breakpoint
and a relative expression ratio was calculated after normalizing to the respec-
tive exon RPKM of the normal control. The minimum exon expression value
was set to 1 RPKM. Further details are in the Supplemental Experimental
Procedures.
Small RNA Sequencing and Analysis
Small RNAs (mainly miRNAs) up to 40 nt were size-fractionated on a
polyacrylamide gel from up to 5 mg mRNA-depleted, DNase-treated
(RNase-free DNase I, QIAGEN, Hilden, Germany) RNA. Small RNA libraries
were prepared using the NEBNext Small RNA Sample Prep Set (NEB,
Frankfurt/M., Germany) as described by the manufacturer, with some modi-
fications (see Supplemental Experimental Procedures for details). Amplicons
of 90–100 bp were sequenced on an Illumina HiSeq2000 instrument (read
length: 50 bp) and mapped to the reference using the miRDeep2 package
(Friedla¨nder et al., 2012).
DNA Methylome Sequencing and Analysis
MCIp for enrichment of highly methylated DNA was performed as described
previously (Gebhard et al., 2006) (see Supplemental Experimental Procedures
for details). For deep-sequencing library preparation with highly methylated
DNA, the NebNext chemistry (New England Biolabs, Ipswich, MA, USA)
and barcoded adaptors compatible with the SOLiD sequencing platform
were used. Single-end 50 bp reads were generated using the SOLiD 4 next-
generation sequencing platform (Applied Biosystems, Life Technologies
Corporation, Carlsbad, CA, USA). Mapped (software BFAST; Homer et al.,
2009) and quality controlled reads were used to identify DMRs between tumor
and normal (further details in the Supplemental Experimental Procedures).
Biallelic Inactivation Inference and Pathway Analysis
We scanned for genes inactivated in a biallelic fashion by extracting loci with
two overlapping events, ie, germline or somatic homozygous nonsynonymous
SNVs or an exon-disrupting deletion overlapping a second gene-disrupting
aberration such as an SNV, deletion, inversion, or translocation. Genes within
deletions were additionally required to have read-depth support. With esti-
mated raw SNV allele frequencies ranging from 0.15 to 0.4, raw SV allele
frequencies estimated to range from 0.20 to 0.45 and estimated tumor purities
of 0.5, the vast majority of intersecting events (eg, a deletion overlapping
a mutation, or gene disruption) occurred on different alleles in the same cell
Cancer Cell
Androgen-Driven Early-Onset Prostate Cancerpopulation (rather than representing subclonal events affecting different cell
subpopulations). For carrying out the pathway enrichment analysis, fusion
genes were extracted and analyzed by Genomatix Genome Analyzer with
standard parameters. The p values were adjusted for multiple-testing by
controlling the FDR according to Benjamini and Hochberg.
PCA Tissue Microarray Resource
Details on the PCA prognosis TMA (earlier described in Schlomm et al., 2008)
used for FISH and IHC analyses are in the Supplemental Experimental
Procedures.
ERG Immunohistochemistry Analysis
ERG IHC using antibody ERG (clone EPR3864, dilution 1:450, Epitomics) was
performed as previously described (Minner et al., 2011). See Supplemental
Experimental Procedures for further details.
FISH Analysis
FISH analysis was performed as previously described before (Minner et al.,
2011). Details on probes are in the Supplemental Experimental Procedures.
TMA Statistical Analysis
Logistic regression analyses were performed using the generalized linear
model glm package in R. Statistical significance and fitness of the models
were verified with the Wald test and likelihood ratio test.
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